Lung Cancer Trial Advanced Pumitamig Dosage in 2026
The ROSETTA Lung-02 study identified a 1500-mg dose of pumitamig plus chemotherapy for future Phase 3 testing.
Updated on Oct. 6, 2026 in Cancer
Data presented at the 2026 ASCO Annual Meeting showed a 62.5% objective response rate for pumitamig plus chemotherapy in patients with advanced NSCLC. Researchers selected a 1500-mg dose for the Phase 3 portion of the trial based on its performance in early stages.
Why it matters
This bispecific antibody aims to improve outcomes for tumors with low PD-L1 expression by bringing cancer cells into closer proximity with T cells. The selection of a 1500-mg dose balances efficacy with the management of VEGF-related adverse events.
The study recorded an objective response rate of 47.6% in patients with a PD-L1 TPS below 1%, while grade 3 VEGF-related events occurred in 4.7% of the total cohort. Pumitamig features a half-life of 4 to 6 days, significantly shorter than the 20-day half-life of bevacizumab.
The players
Solange Peters
She is a lead researcher affiliated with Lausanne University Hospital who specializes in thoracic oncology and clinical trial development.
ASCO
The American Society of Clinical Oncology is a professional organization representing physicians and oncology professionals who care for people living with cancer.
The details
The treatment works by forming complexes with VEGF-A that cluster with PD-L1, leading to internal internalization that facilitates immune activity. Investigators selected the 1500-mg dose through pharmacokinetic and pharmacodynamic modeling to optimize therapeutic results while minimizing toxicity.
Timeline
Data from the ROSETTA Lung-02 trial were presented at the 2026 ASCO Annual Meeting.
Health Landscape
This development in the ROSETTA Lung-02 trial marks a transition in the use of bispecific antibodies to overcome resistance in tumors with low PD-L1 expression. It signals a move toward more precise dosing strategies that manage the toxicity profiles associated with VEGF-targeting therapies.
This research provides a potential future treatment path for patients with advanced NSCLC who exhibit low PD-L1 expression. The identification of a manageable dosage protocol is a critical step toward ensuring these new therapies can safely enter clinical practice.
The takeaway
The ROSETTA Lung-02 trial demonstrates that strategic dose selection is vital for balancing immune-activating benefits against potential VEGF-related side effects. This approach helps refine how clinicians treat complex, low-expression lung tumors using advanced antibody combinations.
Further reading
For more information on the latest clinical developments, visit the Cancer section.
Source note: This article includes information reported by OncLive.
